Trypanosoma type I nitroreductase (NTR1)

Type I nitroreductases (NTRs) are flavin-mononucleotide (FMN)-containing enzymes found in kinetoplastid parasites, including Trypanosoma brucei and Trypanosoma cruzi (Wilkinson et al., 2008, PubMed: 18310072). Unlike mammalian nitroreductases, which typically perform one-electron reductions, these parasitic enzymes are oxygen-insensitive and catalyze a two-electron reduction of nitro groups (Hall & Wilkinson, 2012, PubMed: 22106220). This activity is essential for the bioactivation of clinical prodrugs such as nifurtimox, benznidazole, and fexinidazole (UniProt: Q389T8, Q4D944). The reduction process generates toxic metabolites, including unsaturated nitriles and hydroxylamines, which cause extensive cellular damage through DNA fragmentation and protein adduct formation (PubChem CID: 68424). Because humans lack an equivalent oxygen-insensitive NTR, these enzymes provide a high degree of parasite-specific selectivity. However, the loss or mutation of the NTR gene is a well-documented mechanism of laboratory-derived and potentially clinical resistance to nitroheterocyclic drugs (Wilkinson et al., 2008). These enzymes are localized to the mitochondrion in T. brucei and are critical for maintaining the efficacy of current frontline treatments for African Sleeping Sickness and Chagas disease.

Other names

Oxygen-insensitive nitroreductaseNADH-dependent nitroreductaseType I NTRTbNTRTcNTRNitroreductase 1

Prodrug activation via a two-electron reduction of nitroaromatic compounds to generate cytotoxic reactive intermediates such as hydroxylamines and nitriles.